Fairvalue-Calculator Fairvalue-Calculator
EN DE

Taiwan Bio Therapeutics Co (6892) Fair Value & Analysis

Healthcare · TW · Market cap 2.4B TWD

Price27.40 TWD
Fair Value23.64 TWD
Upside-13.7%
Quality95/100
Evidence: Low Range 17.73 TWD – 29.54 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Taiwan Bio Therapeutics Co (6892) currently trades at 27.40 TWD, while our model-based Fair Value estimate is 23.64 TWD — implying the stock looks roughly 13.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Taiwan Bio Therapeutics Co (6892) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 23.64 TWD versus a price of 27.40 TWD — about −14% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6892?
Our 21-model fair value for Taiwan Bio Therapeutics Co is 23.64 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 27.40 TWD.
What is the quality score of 6892?
Taiwan Bio Therapeutics Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.